Funding for this research was provided by:
NINDS (RO1NS126227, U01NS120901.)
ICAT (203930/B/16/Z)
Article History
Accepted: 17 January 2023
First Online: 13 February 2023
Declarations
:
: Dr. Gilligan is funded by the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), and the Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. Dr. McGuigan reports no disclosures. Dr. McKeon is funded by grants from NIH (RO1NS126227, U01NS120901), and has consulted for Janssen and Roche Pharmaceuticals without personal compensation. Dr. McKeon has patents for Septin-5-IgG and Septin-7-IgG licensed to Euroimmun, a patent for GFAP-IgG issued, a patent for MAP1B-IgG with royalties paid to himself and licensed to Ravo Diagnostika, and patents for KLCHL11-IgG and PDE10A-IgG pending.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).